Limits...
Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.


Related in: MedlinePlus

Forest plots showing the HRs and their corresponding CIs by cancer type subgroups (used a random-effects model).Note: Weights are from random-effects analysis.Abbreviations: CI, confidence interval; HR, hazard ratio.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036562&req=5

f4-ott-9-5771: Forest plots showing the HRs and their corresponding CIs by cancer type subgroups (used a random-effects model).Note: Weights are from random-effects analysis.Abbreviations: CI, confidence interval; HR, hazard ratio.

Mentions: Subgroup analyses were performed according to the following categories: cancer type, region, tissue preservation, and analysis of variance. As the results shown in Figure 4 and Table 3, compared with the total pooled HR, decreased miR-133a exhibited a stronger correlation with poor OS in the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001). In the meantime, these three subgroups also presented relatively low heterogeneity (I2=52.2%, P=0.079; I2=40.5%, P=0.121; and I2=0.0%, P=0.443, respectively) (Table 3). However, subgroups, such as osteosarcoma, NSCLC, formalin-fixed and paraffin-embedded (FFPE) tissue preservation, and univariate analysis, showed no statistically significant association between decreased miR-133a and OS outcome (Table 3).


Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis
Forest plots showing the HRs and their corresponding CIs by cancer type subgroups (used a random-effects model).Note: Weights are from random-effects analysis.Abbreviations: CI, confidence interval; HR, hazard ratio.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036562&req=5

f4-ott-9-5771: Forest plots showing the HRs and their corresponding CIs by cancer type subgroups (used a random-effects model).Note: Weights are from random-effects analysis.Abbreviations: CI, confidence interval; HR, hazard ratio.
Mentions: Subgroup analyses were performed according to the following categories: cancer type, region, tissue preservation, and analysis of variance. As the results shown in Figure 4 and Table 3, compared with the total pooled HR, decreased miR-133a exhibited a stronger correlation with poor OS in the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001). In the meantime, these three subgroups also presented relatively low heterogeneity (I2=52.2%, P=0.079; I2=40.5%, P=0.121; and I2=0.0%, P=0.443, respectively) (Table 3). However, subgroups, such as osteosarcoma, NSCLC, formalin-fixed and paraffin-embedded (FFPE) tissue preservation, and univariate analysis, showed no statistically significant association between decreased miR-133a and OS outcome (Table 3).

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16&ndash;2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20&ndash;2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41&ndash;2.53, P&lt;0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42&ndash;3.02, P&lt;0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.


Related in: MedlinePlus